drugset / Trial / NCT04265274
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC\_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast cancer.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2022-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Copper | Unknown | 2 mg | — |
| Subject | Disulfiram | Small molecule | 400 mg | — |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | — |